Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating efficacy, safety, pharmacodynamics and pharmacokinetics of HBM9161 in patients with Myasthenia Gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• HBM9161

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Myasthenia Gravis | Phase 2 | Status: COMPLETED